

Quality of Life in CML patients - Projects of the German CML Study Group

Ute Kossak, Susanne Sauße

German CML study group QoL project - Phase I

CML studies I-IV: more than 4000 patients randomized

2000 patients are alive and will be contacted

- Three patient cohorts:
 - 1-3 years survival ca. 490
 - 4-7 years survival ca. 740
 - 8 and more years survival ca. 770

Number of patients in treatment groups

Therapy group	1	2	3	4	5	6	total
	1st imatinib	1st IFN 2nd imatinib	2nd generation TKI	SCT	IFN	HU / other	
cohort (years survival)							
1-3	461	0	21	5	0	0	487
4-7	464	63	35	121	58	0	741
8 - 20+	2	122	16	513	87	29	769

Phase I - objectives

main subject:

- differences in QoL of transplanted patients / patients with TKI (survival is equal in transplanted / TKI patients, however, there is a better molecular remission in transplanted patients, Saussele et al. Blood 2009)

other subjects:

- differences in QoL of first- and second line TKI patients
- late effects in transplanted patients compared to TKI patients
- influence of patient specific parameters (age, sex, ...)

Phase II – objectives


- differences in QoL of CML patients that are subject to different therapies?
- Is QoL changing during treatment? (evaluation at diagnosis, after 12 and 24 months)
- specific questionnaires
- prospective evaluation

Phase II – CML V study

Integration of a QoL questionnaire in the
CML study V

- Recruitment: 200 patients per year
- nilotinib vs. nilotinib + interferon alpha
(induction / maintenance)

Time table



... the end.

Thank you for your attention!
Interested in cooperation?

... the beginning ?